Steering Improved Outcomes in Non-driver Mutation Lung Cancer: Progress and Challenges

Steering Improved Outcomes in Non-driver Mutation Lung Cancer: Progress and Challenges


Date of Publication: 12 Nov 2018
Date of Expiration: 11 Nov 2019

How To Claim Credit: After downloading and reviewing the report, click the "To start the quiz click here" button on the penultimate page to complete the self-assessment quiz and request credit.

Target Audience

This activity is designed for oncologists and other healthcare professionals who treat patients with lung cancer.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Describe how the histological and molecular profiling may help to individualise care in nonsquamous and squamous NSCLC from the first-line setting though subsequent lines of treatment
  2. Appraise data from the ongoing trials in the field of non-driver lung cancer and describe how they may maximise patient outcomes
  3. Debate the optimal sequencing and the pros and cons of the different available therapies for lung cancer patients without an actionable oncogenic driver
  4. Identify patients with refractory and/or aggressive disease and how to optimally sequence treatment for these patients in daily clinical practice

This programme is made possible thanks to independent medical educational sponsorship from Eli Lilly and Company.


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and Springer Healthcare. Imedex is accredited by the ACCME to provide continuing medical education for physicians.

Credit statement

Imedex®, LLC designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Disclosure of Relevant Financial Relationships

As an accredited provider of continuing medical education, Imedex, LLC requires anyone in a position to affect the activity’s subject matter to disclose any financial relationships they have as related to the contents of their presentations. The existence of commercial or financial interests of presenters related to the subject matter of their presentations should not be construed as implying bias or decreasing the value of their presentations. However, disclosure should help participants form their own judgments.

All presenters were independently selected by the organizers. Those presenters who disclosed affiliations or financial interests with the commercial organizations involved with products, to which they may refer, are listed below.

Imedex, LLC Staff Disclosure of Financial Relationships
All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:
     Chris Bolwell owns shares of stock of GlaxoSmithKline.

Springer Healthcare (Planner) Disclosure of Financial Relationships
All Springer Healthcare staff members who are in a position to control content of this activity have no financial relationships with any commercial interests.

Unapproved and Investigational Uses of Drugs and Devices

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of Imedex.


Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC. has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician- patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.


Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most quali ed medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR


© 2018 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334